While general recommendations are for 300-mg magnesium intake a day, an advanced low-dose formulation of magnesium chloride, ChronoMag®, was designed to provide 100 mg of magnesium element, thus decreasing the risk of gastrointestinal side effects and allowing long-term supplementation in health conditions related to low magnesium levels. The present study aimed to compare magnesium release profile and bioavailability between this patented low-dose continuous-release magnesium chloride tablet (100 mg magnesium element) and a reference tablet at the usually prescribed dose (300 mg magnesium element). Magnesium release profile was determined by dissolving the tablets in solutions simulating the gastrointestinal tract environment. A randomized double-blind crossover controlled trial of ChronoMag® versus reference tablet (3 × 100 mg magnesium element tablets) in 12 normo-magnesemic healthy volunteers was conducted to evaluate the bioavailability of the patented magnesium chloride tablets (two 50 mg magnesium tablets, once-a-day intake). While the reference tablet released 100% of its magnesium within 1 h of dissolution, release from the magnesium chloride formulation was continuous for 6 h. Cumulative urinary magnesium levels compared to those with the reference tablet were 76% (0-5 h), 89% (0-10 h), and 87% (0-24 h). Elimination after 24 h was fairly similar with both supplements. Our results suggest that the new magnesium chloride formulation, providing continuous low-dose magnesium release throughout the gastrointestinal tract, improves absorption and bioavailability. This formulation conforms to the physiological mechanism of magnesium absorption throughout the digestive tract, allowing high absorption, and may improve gastrointestinal tolerance in long-term use.

Patients suffering from fibromyalgia often report stress and pain, with both often refractory to usual drug treatment. Magnesium supplementation seems to improve fibromyalgia symptoms, but the level of evidence is still poor. This study is a randomized, controlled, double-blind trial in fibromyalgia patients that compared once a day oral magnesium 100 mg (Chronomag®, magnesium chloride technology formula) to placebo, for 1 month. The primary endpoint was the level of stress on the DASS-42 scale, and secondary endpoints were pain, sleep, quality of life, fatigue, catastrophism, social vulnerability, and magnesium blood concentrations. After 1 month of treatment, the DASS-42 score decreased in the magnesium and placebo groups but not significantly (21.8 ± 9.6 vs. 21.6 ± 10.8, respectively, p = 0.930). Magnesium supplementation significantly reduced the mild/moderate stress subgroup (DASS-42 stress score: 22.1 ± 2.8 to 12.3 ± 7.0 in magnesium vs. 21.9 ± 11.9 to 22.9 ± 11.9 in placebo, p = 0.003). Pain severity diminished significantly (p = 0.029) with magnesium while the other parameters were not significantly different between both groups. These findings show, for the first time, that magnesium improves mild/moderate stress and reduces the pain experience in fibromyalgia patients. This suggests that daily magnesium could be a useful treatment to improve the burden of disease of fibromyalgia patients and calls for a larger clinical trial.

Article original Pharmacognosie L'extrait huileux au CO 2 supercritique de baies et de graines d'argousier (Hippophae rhamnoides L.) et ses effets sur la peau et les muqueuses F. Joanny Menvielle-Bourg, Docteur en pharmacie FABIENNE JOANNY Consulting & Licensing 230, rue du Faubourg Saint-Honoré,Résumé : L'extrait huileux d'argousier obtenu selon la technique du CO 2 supercritique combine les actifs des graines et de la pulpe des baies : caroténoïdes, tocophérols, phytostérols et acides gras insaturés, notamment omega-7. Riche de cette association, l'extrait renforce les tissus épithéliaux et stimule leurs capacités de défense. Ainsi, il s'avère efficace, par voie orale, dans le traitement et la prévention d'affections diverses (dermite atopique, ulcère gastrique, syndrome de Sjögren...). En cosmétique interne, il améliore l'hydratation, l'aspect et l'élasticité de la peau. Mots clés : Huile d'argousier -Acides gras oméga-7 -Peau -Muqueuses -Extraction au CO 2 supercritiqueSupercritical CO 2 extracted sea buckthorn (Hippophae rhamnoides L.) pulp and seed oil and its benefits on skin and mucous membranes Abstract: The sea buckthorn oily extract obtained by using supercritical CO 2 technology combines the active principles from both seeds and berry pulp: carotenoids, tocopherols, phytosterols and unsaturated fatty acids, namely the omega-7 series. Thanks to this combination, the extract strengthens epithelial tissues and stimulates their defence systems. It can thus be seen to be effective in treating or preventing various conditions (atopic dermatitis, gastric ulcer, Sjögren's syndrome etc.). In oral cosmetics, it improves skin hydration and elasticity.